Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) CFO Sells 25,000 Shares of Stock

Key Points

• CFO Anthony Bergmann sold 25,000 shares on March 31 at an average price of $30.13 for about $753,250, cutting his holding by 75.25% to 8,223 shares — disclosed via an SEC Form 4.
• CAPR traded near $31.62 (12‑month range $4.30–$40.37) with a market cap of $1.82B and recent negative EPS (−$0.62); analysts have a consensus "Moderate Buy" with an average target of $46.09 and individual targets as high as $62.
• Institutional investors hold meaningful stakes — Vanguard owns roughly 2.56M shares and firms like Suvretta, RA Capital and Geode also built positions, with institutional ownership around 21.68%.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) CFO Anthony Bergmann sold 25,000 shares of the company's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the transaction, the chief financial officer owned 8,223 shares in the company, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Capricor Therapeutics Stock Performance

CAPR traded up $1.50 during midday trading on Thursday, hitting $31.62. The company had a trading volume of 346,173 shares, compared to its average volume of 1,371,751. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37. The company has a market capitalization of $1.82 billion, a PE ratio of -13.99 and a beta of 0.48. The firm's 50-day simple moving average is $27.04 and its 200-day simple moving average is $18.74.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). As a group, sell-side analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company's stock valued at $73,936,000 after purchasing an additional 355,161 shares during the period. Suvretta Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $51,533,000. Tang Capital Management LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at about $49,062,000. RA Capital Management L.P. bought a new stake in Capricor Therapeutics in the fourth quarter valued at about $43,516,000. Finally, Geode Capital Management LLC lifted its stake in Capricor Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company's stock valued at $29,367,000 after buying an additional 55,766 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the company an "overweight" rating in a research report on Friday, March 13th. Piper Sandler reaffirmed an "overweight" rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Wall Street Zen cut Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, January 11th. Oppenheimer lifted their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an "outperform" rating in a research report on Monday, December 8th. Finally, iA Financial set a $48.00 price objective on Capricor Therapeutics in a report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $46.09.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.